Targeting Dopaminergic Mechanisms of Slowing to Improve Late Life Depression
Sponsor: |
NIMH |
Enrolling: |
Male and Female Patients |
Study Length: |
3 Weeks |
IRB Number: |
7270 |
U.S. Govt. ID: |
NCT02744391 |
Contact: |
Veronika Bailey: 646-774-8655 / vbailey@nyspi.columbia.edu |
In this research study, you will receive a medication called carbidopa/levodopa (Sinemet). This medication is approved by the Food and Drug Administration for the treatment of Parkinson's Disease. We are using carbidopa/levodopa off-label in this study to see whether it is capable of improving depressive symptoms as well as mental and physical slowing that occur as people age.
This study is closed
Have you ever been diagnosed with Bipolar Disorder (or manic-depressive illness)? |
Yes |
No |